Skip to main content

Table 1 Major eligibility criteria

From: Effect of rosuvastatin on outcomes in chronic haemodialysis patients – design and rationale of the AURORA study

Inclusion

Men and women aged 50–80 years

End-stage renal failure and chronic haemodialysis for at least 3 months

Provision of written informed consent

Exclusion

Underlying haematological, neoplastic, GI, metabolic (other than diabetes) or infectious condition expected to reduce survival to less than 1 year

Patients likely to require a kidney transplant within 1 year

Statin therapy within the previous 6 months

History of serious reactions to statins

Unexplained CK >3 times ULN

Active liver disease (ALT >3 times ULN)

Uncontrolled hypothyroidism

A disallowed medication, such as another lipid-modifying agent or cyclosporin

  1. ALT: Alanine transaminase, CK: Creatine kinase, GI: Gastrointestinal, ULN: Upper limit of normal